Study_Mentioned
stringlengths 3
205
⌀ | Product_Mentioned
stringlengths 3
429
⌀ | Company_Mentioned
stringlengths 3
288
| Indication_Mentioned
stringlengths 2
111
| Non_Social
int64 1
1
| Tag
stringlengths 2
1.13k
⌀ | Adjusted_Date
stringlengths 11
16
| Conversation_Id
float64 422,000,000B
1,680,000,000B
| Clean_Tweet
stringlengths 1
298
⌀ | Profile_Bio
stringlengths 1
185
⌀ | Class
stringclasses 6
values | User_Type
stringclasses 17
values |
|---|---|---|---|---|---|---|---|---|---|---|---|
DESTINY-Breast03 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'bcsm', 'breast'] | 6/4/2022 18:20 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan remains safe and effective option for metastatic breast cancer #asco22 #bcsm | Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management. | Company / Organization | Publication / Journal |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 7:29 | 1,530,000,000,000,000,000 | the results of destiny-breast04 published in t-dxd in previously treated her2-low abc hr+ cohort pfs; 10.1 vs 5.4 mos,hr:0.51 os; 23.9 vs 17.5 mos,hr:0.64
all pts pfs; 9.9 vs 5.1 mos,hr:0.5 os; 23.4 vs 16.8 mos,hr:0.64 #asco22 | Medical Oncologist | Individual | HCP |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 7:35 | 1,530,000,000,000,000,000 | a new treatment is effective for advanced her2-low breast cancer treatment with trastuzumab deruxtecan increases progression-free survival and overall survival compared with the usual treatments info: #asco22 | Compte oficial de l'Hospital CLÍNIC de Barcelona. Tota l'actualitat en assistència i recerca. | Company / Organization | Hospital / Clinic |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', '$azn'] | 6/5/2022 10:11 | 1,530,000,000,000,000,000 | #asco22: enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way
(a legacy of the late jose baselga's turn at $azn) | Founder, EIC of Endpoints News: The biopharma world is here -- 144,000 global industry subscribers. We work for it. #sweatequity john@endpointsnews.com | Individual | Publication / Journal |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 12:34 | 1,530,000,000,000,000,000 | updated: #asco22: enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way endpoints news | Executive Director. Member NYU @CUPAEthics and NYU PGTME. GE2P2 Independent Bioethics Advisory Committee. MHSc Candidate, UofT. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:30 | 1,530,000,000,000,000,000 | discuss the destiny-breast04 study with our dr. naoto ueno by visiting booth 6122 tomorrow, monday, june 6 from 10-11 a.m. #asco22 #endcancer | The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789. | Company / Organization | Hospital / Clinic |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny04'] | 6/5/2022 14:36 | 1,530,000,000,000,000,000 | t-dxt destiny04 presentation gets an standing ovation in #asco22 and immediate change in practice with this drug. also a confirmation of the future of third generation adcs in oncology. | Esposo, papá, Médico | Individual | HCP |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'mbc'] | 6/5/2022 14:37 | 1,530,000,000,000,000,000 | 2005 as a fellow at my 1st asco in orlando i saw a standing ovation to the result of adjuvant trastuzumab in her2 pos ebc. today 2022 post a horrible two years of isolation from covid i see a standing ovation to the results of t dxd in her2 low mbc. #asco2022 #asco22 | Breast cancer specialist. Shoe lover. Cupcake connoisseuse. Opinions are my own, RTs not an endorsement. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast'] | 6/5/2022 14:44 | 1,530,000,000,000,000,000 | #asco22 destiny-breast 04 received a standing ovation at the plenary session! exciting data and practice changing for our #breastcancer patients! | Hematology/Oncology Fellow @UMiamiMedicine @JacksonHealth @SylvesterCancer | Tweets are my own. ???????? #Sarcoma #BreastCancer | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['congrat', 'bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:51 | 1,530,000,000,000,000,000 | destiny-breast04 did not disappoint! t-dxd benefit over chemotherapy in her2-low previously treated advanced bc regardless of hr status hazard ratio=0.5. congrats dr modi and investigators #asco22 #plenary #bcsm | CME experts Sara Fagerlie, PhD, CHCP and Mindy Tanzola, PhD founded Front Row CME to help clinicians and educators manage the oncology information deluge. | Company / Organization | Healthcare |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['inspire', 'breast', 'destinybreast04'] | 6/5/2022 16:40 | 1,530,000,000,000,000,000 | check out our manuscript in looking at patients with #hrlow #breastcancer. inspired by the #destinybreast04 data presented at #asco2022. it's time to re-think how we categorize these breast cancer subtypes. #hrlow #her2low | Heme/Onc Fellow @uw_hemeoncpc | Class of 2021 @uw_IMresidency I Class of 2018 @rushumedcollege | Class of 2013 @UMich | #WomeninMedicine. Views are my own. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['dance', 'bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 17:59 | 1,530,000,000,000,000,000 | practice-changing results from destiny-breast04 were presented at #asco22 today! ild/pneumonitis rate of 12%. excellent time to review guidance on the diagnosis & management of t-dxd-related ild/pneumonitis by et al. #bcsm | Chief Heme/Onc Education Fellow @MDAndersonNews | Alum of @dukeu @muschealth @vumchealth | Interest in #meded ??#cancer #lcsm | Tweets my own ? medical advice | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny04'] | 6/5/2022 20:07 | 1,530,000,000,000,000,000 | nice destiny04 summary of efficacy & safety #asco22 | Translational Medical Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data) @OncoAlert. Motto: "Let's make a difference". Views mine. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast'] | 6/6/2022 5:54 | 1,530,000,000,000,000,000 | the #oncoalerttoptweet day 3 #asco22 tweet #destinybreast04 trial at #asco22 plenary session one of the most important moment in the history of this disease #breastcancer best, | ?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ?? | Bot / Aggregator | Media / News |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'destiny-breast04', 'enhertu', 'astrazeneca', 'daiichi'] | 6/6/2022 8:41 | 1,530,000,000,000,000,000 | the destiny-breast04 trial looks predestined to launch enhertu into the her2-low unresectable or metastatic breast cancer setting. how practice-changing will this data from astrazeneca and daiichisankyo be? #asco22 #oncology #breastcancer | Bringing remarkable clarity to life sciences’ and healthcare's most important decisions. | Company / Organization | Pharma / Biotech |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 11:03 | 1,530,000,000,000,000,000 | given the overall survival benefit this is practice-changing and will potentially open up treatment for a whole new group of patients, says our dr. jennifer litton of enhertu for patients with advanced breast cancer. #asco22 #endcancer | Driven by our mission to #EndCancer, MD Anderson is a leader in cancer care, research, education and training, and prevention. Appointments: 1-877-632-6789 | Company / Organization | Hospital / Clinic |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'enhertu'] | 6/6/2022 11:11 | 1,530,000,000,000,000,000 | enhertu could transform #breastcancer treatment, landmark her2-low trial suggests. #asco22 #bcsm | Medscape provides breaking medical news and expert perspectives, drug and disease information, and free CME across 30+ medical specialties. | Company / Organization | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'destiny,breast,4', 'breast', 'destiny-breast04'] | 6/6/2022 11:52 | 1,530,000,000,000,000,000 | "a beautiful, powerful moment, that will remain in the history of breast oncology," says of the standing ovation after the #asco22 plenary presentation of destiny-breast04 by shanu modi, md, of . #bcsm | OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals. | Company / Organization | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast'] | 6/6/2022 13:41 | 1,530,000,000,000,000,000 | missing #asco22 #asco2022? i will cover all the papers in this playlist. way better than the conference. for one, more accurate/ balanced destiny breast 04 today/ tomorrow | Medicine Oncology Science Policy
Academic Pubs @vkprasadlab
Podcast @plenary_session
Clips on YouTube ??
Books EMR & Malignant
Prof @ucsf_epibiostat
Views mine | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 13:54 | 1,530,000,000,000,000,000 | fascinating discussions ongoing in #breastcancer oncology circles on reliability of her-2 evaluation by #pathologists following #asco22 enhertu data in low her-2 cancers. members of my tribe - are you ready to draw the line in the sand between true her-2 zero & everything else? | Pancreatic cancer researcher and GI pathologist. Striving to improve the lives of patients with cancer. | Individual | HCP |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04', 'enhertu'] | 6/6/2022 20:09 | 1,530,000,000,000,000,000 | exciting results announced at #asco22 from the destiny-breast04 trial confirm that the antibody-drug conjugate fam-trastuzumab deruxtecan (enhertu) can be used to treat certain patients with her2-low unresectable and/or metastatic breast cancer. | A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ | Company / Organization | Advocacy / Charity |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 7:07 | 1,530,000,000,000,000,000 | dr. modi breaks down some of the findings in the destiny-breast04 trial. #bcsm #asco22 | The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences | Company / Organization | Hospital / Clinic |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04', 'daiichisankyous', 'astrazenecaus', 'astrazeneca'] | 6/5/2022 7:12 | 1,530,000,000,000,000,000 | new data from the destiny-breast04 trial for certain patients with her2-low metastatic #breastcancer were presented at #asco22 with our collaborators and published in . read more: | The official Twitter feed for AstraZeneca US. For more info visit http://t.co/5VlUaVGyiC. | Company / Organization | Pharma / Biotech |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['tnbc', 'destiny04', 'bcsm'] | 6/5/2022 8:16 | 1,530,000,000,000,000,000 | destiny04 (t-dxd vs chemo tpc) is out on a game-changer for advanced line (1-2 prior chemo lines) her2-low bc #bcsm overall (hr+ and tnbc):
mpfs 9.9 vs 5.1 mos (hr 0.50, p<0 .001)
os 23.4 vs 16.8 mos (hr 0.64, p=0.001) see #asco22 plenary today! | null | Individual | HCP |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'bcsm', 'breast'] | 6/5/2022 9:00 | 1,530,000,000,000,000,000 | #asco22 research: trastuzumab deruxtecan doubles progression-free survival in #metastatic #breastcancer with low her2 expression levels #targetedtherapy #precisionmedicine #cancerresearch #bcsm #patienteducation | Timely, trusted, compassionate doctor-approved info from @ASCO
https://t.co/K04SLVsoar
We cannot answer individual medical questions.
Retweet ?Endorsement | Bot / Aggregator | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04', 'daiichisankyous', 'astrazenecaus', 'astrazeneca'] | 6/5/2022 9:12 | 1,530,000,000,000,000,000 | attending #asco22? join us as we present the highly anticipated destiny-breast04 phase iii trial data in certain patients with her2-low metastatic #breastcancer with our collaborators . | The official Twitter feed for AstraZeneca US. For more info visit http://t.co/5VlUaVGyiC. | Company / Organization | Pharma / Biotech |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'destiny04', 'bcsm', 'breast'] | 6/5/2022 9:59 | 1,530,000,000,000,000,000 | destiny04: in patients with her2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer pfs(10 vs 5 mo) and os (23 vs 17mo) than chemotherapy. grade 3/4 ae: 53%
ild: 12%
#asco22 #bcsm | Breast Oncologist at @MontefioreNYC @EinsteinMed. Interested in Translational Research & Clinical Trials. Diversity & Inclusion. On weekends ???????
???? ???? | Individual | HCP |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 10:08 | 1,530,000,000,000,000,000 | asco: astrazeneca, daiichi's enhertu could transform breast cancer treatment with landmark her2-low show - fiercepharma #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #healthcare #pharma #biotech | Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines | Individual | Finance / Investment |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['enhertu'] | 6/5/2022 12:47 | 1,530,000,000,000,000,000 | i was going to go for drinks last night but i was told it give ilds. always avoid ilds and enhertu. very toxic drug, unlike other effective therapies. rather die from cancer. #asco22 | Official ?? (???) fan account. Online content creator, exclusively @onlyfans She/Her/Hers. | Individual | Finance / Investment |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast', 'astrazenecaus', 'astrazeneca'] | 6/5/2022 12:53 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan cuts risk of disease progression or death by 50% for patients with her2-low metastatic breast cancer #asco22 via | Health is a state of mind. Practicing #yoga. Fan of @onepeloton, @Eagles @SJUHawks, and all things #NOLA. | Individual | Blogger / Random / Other |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'bcsm', 'breast'] | 6/5/2022 14:16 | 1,530,000,000,000,000,000 | fam-trastuzumab deruxtecan-nxki doubles progression-free survival in her2-low metastatic breast cancer #bcsm #oncology #cancer #immunotherapy #asco22 | News and views from the world of clinical oncology and hematology | Company / Organization | Publication / Journal |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:26 | 1,530,000,000,000,000,000 | destiny-breast04: t-dxd vs chemo for her2-low hr+ #metastaticbreastcancer 52.6% vs 16.3% 10.1 vs 5.4 mo 0.51 23.9 vs 17.5 mo 0.64 grade 3+ aes were more frequent in chemo arm ild rate 12.1% #asco22 #bcsm | Physician Scientist/Breast Oncology specialist @mdandersonnews - ????????Views are mine; Retweet ? endorsement; Scientific advisory board member @LobularBCA | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | highly anticipated destiny-breast04 results! wow, standing ovation from the audience, just amazing results for our patients. new standard of care in her-2 low mbc. #bcsm #asco22 | Breast Medical Oncologist @UTHealthSAMDA. Former Heme/Onc Fellow @MontefioreNYC. Former IM resident @UTHimres. Alum @UNC. Dog Mom #breastcancer #BCSM | Individual | HCP |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 14:38 | 1,530,000,000,000,000,000 | in this practice changing trial involving patients with her2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician s choice of chemotherapy. #asco22 | Physician, Precision Oncology, Researcher, Cancer Expert, CEO Protean Biodiagnostics. Professor Oncology and Pathology. | Individual | Pharma / Biotech |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['lba3 '] | 6/5/2022 14:38 | 1,530,000,000,000,000,000 | wow, that ovation for lba3 in the plenary at #asco22 made me a bit emotional | Thinking aloud about scientific and medical research while I listen to random music. Chief Editor at Nat Rev Clin Onc. Views my own. | Individual | Research / Science |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['biomarker', 'lba3 '] | 6/5/2022 14:50 | 1,530,000,000,000,000,000 | dr. lorusso lba3 #asco22: we need better biomarker assays too! (+2 applause lines including 1 for pres. obama) | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:52 | 1,530,000,000,000,000,000 | amazing discussion and precious message by dr. patricia lorusso! #destiny-breast04 #asco22 | Medical Director Clinical Operations, Cancer Survivorship Program; Breast Oncologist @SylvesterCancer, AD of Community Outreach. #WomenInMedicine tweets=my own | Individual | HCP |
DESTINY-Breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 16:46 | 1,530,000,000,000,000,000 | #asco : #astrazeneca, daiichi's enhertu could transform breast cancer [ ] the fda has lifted the clinical hold on ocugen's phase 2/3 study of bharat #biotech's #covid19 vaccine covaxin, which is approved in #india and boasts | Journaliste Français indépendant installé en Suisse, Observateur spécialisé en analyse de reportages et de témoignages internationaux diffusé sur le web | Company / Organization | Blogger / Random / Other |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 1:16 | 1,510,000,000,000,000,000 | 11. enhertu wows #asco22 and redefines the treatment of her2 low expressing breast cancer. | #Biotech investor, index provider, entrepreneur, creator of two Nasdaq-listed exchange traded funds, KC native, @univmiami hurricane.???? | Individual | Finance / Investment |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast', 'trastuzumab'] | 6/6/2022 4:27 | 1,530,000,000,000,000,000 | great to see such positive results from #destinybreast04 at #asco22. presumably all down to the improved features of trastuzumab deruxtecan vs. trastuzumab emtansine. illustrations attached! | Cancer educator | training provider | science communicator | writer | teacher of cancer biology & targeted cancer treatments | Individual | Research / Science |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other,thoracic | 1 | ['bcsm', 'lung', 'breast', 'enhertu'] | 6/6/2022 9:08 | 1,530,000,000,000,000,000 | promising development for those w/ #her2low #breastcancer but ... there were #ses for some.
"around 12% of patients who were treated w/enhertu developed a lung disease."
#bcsm
___________________________
#asco22: enhertu blows chemotherapy out of the water | Everything was going great until this whole breast cancer thing. | Individual | Advocacy / Charity |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'bcsm', 'destiny,breast,4', 'breast', 'trastuzumab'] | 6/6/2022 9:41 | 1,530,000,000,000,000,000 | #asco22
#destinybreast04 opens a new era for metastatic #breastcancer classification and treatment #her2negative will never be the same again #her2low #trastuzumabderuxtecan #bcsm #shanumodi #davidcameron | Medonc at dpt of general medical oncology @UZleuven ????Knight to improve outcome of breast cancer pts ???? #TNBC #BCY #HereditaryCancerSyndromes | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'destiny-breast04'] | 6/6/2022 9:51 | 1,530,000,000,000,000,000 | i summed up the destiny-breast04 data for patients over on ig. check it out and share if you find it helpful! #asco22 | Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ?? | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 10:22 | 1,530,000,000,000,000,000 | enhertu could transform #breastcancer treatment, landmark her2-low trial suggests. #asco22 | Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME. | Company / Organization | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'destiny-breast04'] | 6/6/2022 10:54 | 1,530,000,000,000,000,000 | we published this paper around er/her2 co expression in 2014 and below is part of the discussion. what we thought of as research back then is now part of breast practice with the remarkable destiny-breast04 #asco2022 | Breast Oncologist. Endocrine Resistance, triple + BC, Breast CA in men. Stanford, Baylor, Markey, Jordan. Life revolves around my 2 boys. | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca', 'daiichi'] | 6/6/2022 14:04 | 1,530,000,000,000,000,000 | asco: astrazeneca, daiichi s enhertu could transform breast cancer treatment with landmark her2-low show | #health Communications champion of innovation, patient centricity & science. lucky wife/mom, enthusiastic adventurer, people connector #biotech #medtech #Hoya | Individual | Healthcare |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', ' vision', 'breast', 'destiny-breast04'] | 6/6/2022 6:50 | 1,530,000,000,000,000,000 | in the days leading up to #asco22 i did a tweet series on the idea of a #21stcenturyprintingpress in my #tedx talk in dublin, ireland, i said that people are the "moveable type" of this new world of information. this standing ovation for destiny-breast04 symbolizes the vision. | GM, Community & Experiences, Executive Council | TEDx Speaker | Chair, Side-Out Foundation | Maureen, my love, passed 10.21.2014 of #breastcancer #SheisMyWhy | Individual | Blogger / Random / Other |
destiny-breast03 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'destiny-breast03', 'breast'] | 6/4/2022 13:28 | 1,530,000,000,000,000,000 | great presentation from with updated safety data from destiny-breast03. no new safety signals emerged. most events g1/g2. 8% ild pneumonitis leading to d/c of t-dxd. higher n/v, fatigue and alopecia in t-dxd arm in initial treatment cycles. #bcsm #asco22 | Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ?? | Individual | HCP |
destiny-breast07 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-breast07', 'breast', 'daiichisankyous'] | 6/5/2022 5:34 | 1,530,000,000,000,000,000 | today at #asco22: attend our poster presentations on the destiny-breast07 study and the destiny-breast08 study in patients with #her2 expressing #breastcancer. | Daiichi Sankyo US’s channel featuring our biopharmaceutical news, passion for innovation & compassion for patients. See our guidelines: https://t.co/4iEAbpw1Wx | Company / Organization | Pharma / Biotech |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'destiny-breast04', '$azn', '$dsnky'] | 6/5/2022 7:30 | 1,530,000,000,000,000,000 | an impressive chart from the nejm destiny-breast04 publication. enhertu responses across both measures of her2 expression (low and very low!) and er-neg disease. $azn $dsnky #asco22 | Pharma and biotech reporter, found a home at Evaluate Vantage. | Individual | Media / News |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 7:53 | 1,530,000,000,000,000,000 | looks like enhertu is the 'winner' of the asco breast cancer sweepstakes. | Breast cancer specialist and professor @DanaFarber Cancer Institute and @HarvardMed. Tweets are my own and not medical advice. COI disclosure: no COI. | Individual | HCP |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', '$azn', '$dsnky'] | 6/5/2022 7:54 | 1,530,000,000,000,000,000 | enhertu nearly halves risk of disease progression in her2-low breast cancer study $azn $dsnky #asco22 | The latest global #pharma news, insights, analysis, and views providing you with an information edge. FirstWord Pharma. Where people who know first, go first. | Company / Organization | Media / News |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'fierce', 'astrazeneca'] | 6/5/2022 8:00 | 1,530,000,000,000,000,000 | asco: astrazeneca, daiichi's enhertu could transform breast cancer treatment with landmark her2-low show - fiercepharma | @nwnthn x FrDsign. Hourly links to free design courses. | Bot / Aggregator | Blogger / Random / Other |
DESTINY-Breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', '$azn'] | 6/5/2022 8:42 | 1,530,000,000,000,000,000 | does what we've seen from destiny breast 04 already back enhertu approval in her2-low irrespective of er status? $azn $dskny #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 9:10 | 1,530,000,000,000,000,000 | the results of destiny-breast04 published in #asco22 | Narjust Duma, MD, (@NarjustDumaMD) #LCSM Oncologist from @DanaFarber, takes over our Twitter today to discuss #ASCO22. | Company / Organization | Media / News |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'bcsm', 'breast'] | 6/5/2022 10:23 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan demonstrates favorable safety profile in her+ metastatic breast cancer #breastcancer #bcsm #oncology #asco22 | Your online destination for Oncology Nursing news, clinical insights, and resources. | Company / Organization | Media / News |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['trastuzumab'] | 6/5/2022 10:23 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan in her2-positive biliary tract cancer (herb trial) #precisionmedicine at #asco22 | Molecular Precision Oncology ?? #CovidCancerVisionProject Molecular Precision Medicine @MedUni_Wien | Individual | Research / Science |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', '$azn', '$dsnky', 'astrazeneca'] | 6/5/2022 10:24 | 1,530,000,000,000,000,000 | $azn $dsnky asco: astrazeneca, daiichi s enhertu could transform breast cancer treatment with landmark her2-low show | News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities | Individual | Finance / Investment |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04', 'astrazenecaus', 'astrazeneca'] | 6/5/2022 10:29 | 1,530,000,000,000,000,000 | top story: drugs & pharma cos news : 'attending #asco22? join us as we present the highly anticipated destiny-breast04 phase iii trial data in certain patients with her2-low metastatic #breastcancer with o see more | Born in Italy, 1969. | Bot / Aggregator | Blogger / Random / Other |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 10:46 | 1,530,000,000,000,000,000 | #asco22: enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way #strategy #competitiveintelligence #marketing #pharma #biotech #productmarketing #pharmaceutical #healthcare | Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines | Individual | Finance / Investment |
Not Tagged | Not Tagged | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'astrazeneca'] | 6/5/2022 10:49 | 1,530,000,000,000,000,000 | really positive news for breast cancer treatment: an astrazeneca/daiichi drug sharply raises survival rate among patients and could transform how doctors treat the disease in the future #asco2022 | US pharmaceutical correspondent Financial Times - DM's open for any scoops/ ideas or positive comments https://t.co/qoBUXxWpgz… | Individual | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'breast'] | 6/5/2022 10:52 | 1,530,000,000,000,000,000 | destiny breast 04. this is what we will see today in the plenary at asco majority of pts had received more than three lines of therapy in the metastatic setting. this is practice changing. we now have a new standard for our pts with her2 low mbc! #asco2022 | A dedicated conference for oncology held under the theme "Access. Educate. Collaborate" | Company / Organization | Professional |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca'] | 6/5/2022 11:00 | 1,530,000,000,000,000,000 | astrazeneca and daiichi set a new standard in her2-negative breast cancer with enhertu data at #asco22, broadening poc for adcs | The leading voice for decision-makers throughout the global biopharma ecosystem.
Free weekly podcast "BioCentury This Week": https://t.co/6CfHh0mIT6 | Company / Organization | Consulting / Analytics |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'mbc', 'bcsm'] | 6/5/2022 11:55 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan is new standard of care for her2-low mbc #bcsm #asco22 | SVP, Content @MJHLifeSciences. Focused on creating innovative, expert-driven content @OncLive @MedEconomics @AJMC_Journal @Pharmacy_Times @MDMagazine plus more | Individual | Publication / Journal |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 12:42 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | nejm practice changing study #oncology #asco22 | ????? ????? ? ????? ????? #oncology | Individual | HCP |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast', '$azn'] | 6/5/2022 12:55 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan cuts risk of disease progression or death by 50% for patients with her2-low metastatic breast cancer #asco22 $azn | Evidence-Based #Oncology. Bringing together perspectives of 20,000+ cancer care #providers, #payers, #policymakers, #patients, and researchers in #cancer care. | Company / Organization | Publication / Journal |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'mbc'] | 6/5/2022 14:20 | 1,530,000,000,000,000,000 | #asco2022 modi plenary talk on trastuzumab deruxtecan for her2-low mbcl. phase. 3 trial randomized her2-low pts to t-dxd or treatment of physicians choice. tpc options include cape, eribilin, gem, paclitaxel or nab-pac with pfs as primary endpoint and os secondary. | Professor of Medicine, Stanford University; breast cancer doc | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04', 'bcsm'] | 6/5/2022 14:20 | 1,530,000,000,000,000,000 | #asco22 journals getting more enthusiastic and efficient with concurrent publications. now destiny-04 #bcsm #her2 overall survival was 23.4 months and 16.8 months. will see how it translates to other tumor types. #her2 | Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22 | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['panitumumab', 'breast'] | 6/5/2022 14:27 | 1,530,000,000,000,000,000 | we should seriously consider the panitumumab-dxd. certainly it would be a success #asco22. impressive results for destiny-breast-04 | ??????????? ??? ????????. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer. | Individual | HCP |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'bcsm'] | 6/5/2022 14:29 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan works better than chemo in patients with her2-low (previously known as her2-negative) as therapies get more powerful, we need better ways of measuring her2!
#asco22 #bcsm | Geriatric Oncologist @incmnszmx #gerionc, Global Oncology. @ASCO BOD 20-24, FASCO. PhD @UNAM_MX Opinions my own. No FCOI. ???? https://t.co/GruVow1We8… | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny breast04', 'breast', 'in person'] | 6/5/2022 14:32 | 1,530,000,000,000,000,000 | #asco2022 destiny breast04 stunning, practice changing data. clinically meaningful improvements in pfs and os in all analyses. os 23.4 mo vs 17.5 no in all patients. tears of joy, this will lead to more advances. lucky to be here in person | Med Director, Clinical researcher, Breast Cancer Oncologist @bonsecours. What do oncology and bourbon have in common? ME. Tweets my own, free ?? reviews; he/his | Individual | HCP |
destiny-breast04 | trastuzumab | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 14:32 | 1,530,000,000,000,000,000 | #asco22 #trastuzumabderuxtecan in previously treated her2-low advanced #breastcancer | nejm | null | Individual | HCP |
destiny-breast04 | trastuzumab | astrazeneca,daiichi sankyo | other | 1 | ['tnbc', 'trastuzumab', 'mbc'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | new standard of care in her2 low mbc with trastuzumab-deruxtecan not only in rh+ sub population but also in tnbc. amazing results #asco22 #breatcancer #trastuzumabderuxtexan | null | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:34 | 1,530,000,000,000,000,000 | #asco2022 - #mlmasco - d j vu, thank her2 for just being there -destiny-breast04. history on the making | "What we cannot speak about we must pass over in silence" (L. Wittgenstein) | Individual | Blogger / Random / Other |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'breast', 'destiny-breast04'] | 6/5/2022 14:34 | 1,530,000,000,000,000,000 | t-dxd as new soc therapy option for her-2 low metastatic breast cancer (mbc) failing prior therapy based on destiny-breast04 ph3rct received with huge audience applaud! #asco22 | Regional Cancer Research Director @CleveClinicFl #Scientist #Immune #Oncology #Epigenetics #Cancer #Sensitisation #TIME #StayPositive. Tweets are mine. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['lba3 '] | 6/5/2022 14:34 | 1,530,000,000,000,000,000 | dr. lorusso lba3 #asco22: mechanism of action of t-dxd; important point is that the bystander effect is that the drug is membran-permeable | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'destiny-breast04', '$azn', '$dsnky'] | 6/5/2022 14:35 | 1,530,000,000,000,000,000 | destiny-breast04 presentation and shanu modi getting a standing ovation at #asco22 plenary session. reviewer patricia lorusso also says results are "very exciting". enhertu officially wins asco. $azn $dsnky. | Pharma and biotech reporter, found a home at Evaluate Vantage. | Individual | Media / News |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['trastuzumab'] | 6/5/2022 14:41 | 1,530,000,000,000,000,000 | i was at when trastuzumab was 1st presented for the tt of met disease, making a big dif for pts worldwide, later moving to earlier lines. today i witnessed the #onctwitter standing o to tdxd. proud to be an oncologist and to be here in this moment. | Passionate oncologist. CMO @CarismaTher #CARmacrophages for cancer treatment https://t.co/pBNjpNCox5 BOD @americancancer @tigerlilycares @wearearovella | Individual | HCP |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['pearl', 'breast', 'destiny-breast04'] | 6/5/2022 14:56 | 1,530,000,000,000,000,000 | inspiring discussion by dr. lorusso on destiny-breast04 trial. i'm not a breast ca expert but she left us with this pearl. #asco22 | null | Individual | HCP |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'destiny-breast04'] | 6/5/2022 14:57 | 1,530,000,000,000,000,000 | standing ovation for destiny-breast04 data release, practice-changing option for women with "her2low" breast cancer #asco22 #tdxd #enhertu -- honored to be part of daiichi sankyo bringing this treatment option forward for patients! | this is my personal Twitter, no affiliation with my professional work or clients | Individual | Blogger / Random / Other |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['brca'] | 6/5/2022 14:59 | 1,530,000,000,000,000,000 | oh snap!! dr. lorusso quoting in closing remarks following her discussion of the #destiny trial outlining os benefits of #her2-directed therapy for low her2+ #brca expertly presented by dr. shanu modi during #asco22 plenary! | MD-PhD; Radiation oncologist with a passion for health equity; addressing health literacy; loving patients & advocates; empowering individuals & communities. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 15:00 | 1,530,000,000,000,000,000 | what will the late-breaking data from destiny-breast04, presented at #asco22, mean in clinical practice? stay tuned for 's take on the data on t-dxd in her2-low mbc.
keep an on your inbox next week for the cor2ed update from asco! #breastcancer #meded #bcsm | COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally. #COR2ED #MedEd #IME | Company / Organization | Healthcare |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | thoracic,gi,other | 1 | ['lcsm,(-blcsm)', 'crcsm', 'bcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'breast', 'destiny-breast04', 'gastric'] | 6/5/2022 15:00 | 1,530,000,000,000,000,000 | great commentary by on destiny-breast04. 1) need more sensitive her2 expression tests ie that developed by david rimm 2) t-dxd holds promise for other tumors ie gastric #lcsm #crcsm. 3) need to understand resistance mechanisms. #asco22 #bcsm | Mother of Warlords & Slayer of Cancers|Brst/Gyn #radonc @WeillCornell @nyphospital @nypbrooklyn | #globaloncology | #globalhealth|#MedEd|#gyncsm|#bcsm???????? | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 15:23 | 1,530,000,000,000,000,000 | presented at the #asco22 plenary session, the destiny-breast04 trial demonstrates t-dxd treatment leads to improvements in progression-free survival, overall survival for patients with her2-low #metastatic #breastcancer 1/3 | A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ | Company / Organization | Advocacy / Charity |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04'] | 6/5/2022 15:59 | 1,530,000,000,000,000,000 | want to know more about destiny-04? is on the case! #asco22 #obroncology | Executive Managing Editor of #OBROncology (https://t.co/XW1VL90pYg) and #PatientPower (https://t.co/WHsQe8gmv5) at Remedy Health Media. Opinions are mine. | Individual | Publication / Journal |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny breast04', 'breast'] | 6/5/2022 16:11 | 1,530,000,000,000,000,000 | feeling all the feels at #asco22 with presentation of destiny breast04 but mainly excitement for our patients! | Breast Oncology @Stanfordcancer; Former Fellow @Yalecancer; Former IM resident and chief resident at Georgetown; views are my own | Individual | HCP |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast', 'destiny-breast04'] | 6/5/2022 18:48 | 1,530,000,000,000,000,000 | dr shanu modi updates ecancer at #asco22 on the destiny-breast04 trial: trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression | ecancer is a charity with a mission to raise the standards of care for cancer patients across the world through education. #openaccess | Company / Organization | Advocacy / Charity |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04', 'bcsm', 'breast'] | 6/5/2022 19:56 | 1,530,000,000,000,000,000 | #asco22 trendy: her-2 ihc 1+ and 2+ immunohistochemistry path report in breast cancer is now oldie but goldie. #bcsm destiny-04 | Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destinybreast04'] | 6/5/2022 21:09 | 1,530,000,000,000,000,000 | the results of the #destinybreast04 trial are so impressive! as an #immunologist i love following meetings such as #asco22 that overlap with my own practice as i always learn something new! this will be a game changer for many patients! | FRCPC Internal Medicine - Clinical Immunology & Allergy. Lifelong learner, inspired by those around me! Views are my own.?? | Individual | HCP |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['paradigm', 'breast', 'enhertu', 'astrazeneca'] | 6/6/2022 0:54 | 1,530,000,000,000,000,000 | asco: astrazeneca's enhertu is poised to change the breast cancer paradigm | Tokyo-based Editor-in-Chief, Asia-Pacific, for @PharmaScrip @PharmaPinkSheet, @Pharma_Intell. All views my own, RTs not endorsements. | Individual | Media / News |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca', 'astrazenecaus'] | 6/6/2022 4:00 | 422,000,000,000,000,000 | enhertu reduced the risk of disease progression or death by 50% vs. #chemotherapy #asco22 we can extend the time until the #cancer comes back & extend survival such brilliant news from for #breastcancer patients | Conkers3 works with the #investing/corporate world to promote their insights via bespoke interviews/#podcasts/events. Peter is a #Charity Ambassador @MenphysUK | Individual | Finance / Investment |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast'] | 6/6/2022 5:08 | 1,530,000,000,000,000,000 | standing ovation for #destinybreast04 at #asco2022 was incredible! such a practice changing trial! | Medical Oncologist, Moscow Comprehensive Cancer Centre 62, focused on Breast cancer and Lung cancer | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 6:16 | 1,530,000,000,000,000,000 | #enhertu greatly benefits #her2-negative breast cancer patients. #asco #cancer #breastcancer | Sales professional who loves finding solutions to scientific challenges. #Sciencefiction aficionado & #triathlete. Pronouns: he/him/his. Opinions are my own. | Individual | Consulting / Analytics |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca'] | 6/6/2022 7:01 | 1,530,000,000,000,000,000 | such awesome news at #asco22 from chatrick paul and camille hertzka at ! the #enhertu data could open a whole new field of opportunities. #enhertu cut the risk of disease progression or death by half. #breastcancer #cancer #asco #oncology | ?? Lisbon ????????
?? #pharmaceuticals #healthcare #AI
?? Leveraging tech & data to address challenges to Patient Care & HCP engagement #CXStrategy | Individual | Consulting / Analytics |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['db04'] | 6/6/2022 7:07 | 1,530,000,000,000,000,000 | incredible results from db04 at #asco22 published in nejm. | Medical Oncologist at Sunnybrook Odette Cancer Centre
Assistant Professor, Department of Medicine, University of Toronto | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 7:15 | 1,530,000,000,000,000,000 | "the results are phenomenally spectacular, ken takeshita, m.d. #asco2022 #enhertu #breastcancer #her2 | My passion is to improve outcomes for healthcare. | Individual | Healthcare |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['paradigm', 'breast', 'enhertu'] | 6/6/2022 7:36 | 1,530,000,000,000,000,000 | enhertu benefit in her2-low breast cancer wows at asco; signals shifting therapy, dx paradigms more medical news at #oncology #medtwitter #meded #mednews | #Oncology news from major publishers consolidated for a more streamlined industry news experience.???? | Bot / Aggregator | Media / News |
destiny-breast04 | trastuzumab | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'trastuzumab'] | 6/6/2022 8:00 | 1,530,000,000,000,000,000 | from : #trastuzumabderuxtecan in previously treated her2-low advanced #breastcancer | #editorspicks #asco22 | A selective open access journal from @NaturePortfolio publishing research, reviews & commentary across clinical, translational & public health research fields | Company / Organization | Publication / Journal |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04'] | 6/6/2022 8:41 | 1,530,000,000,000,000,000 | just arrived home from #asco22 and still not over some of the presentations we witnessed. in particular, destiny-04: t-dxd for hr+/- her2low hormone resistant metastatic bc and how it significantly improved both pfs & os. absolutely life changing for so many women | Clinical Cancer researcher????????? cat mom ?? musical lover ?? book worm ?? womens health advocate ??Swiftie ??????? Views my own | Individual | Research / Science |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny breast04', 'destiny,breast,4', 'thank you', 'breast'] | 6/6/2022 9:17 | 1,530,000,000,000,000,000 | best comment about destiny breast04 i have read so far. thank you! standing ovation when low-resource countries can have access to these drugs! | Breast Cancer Medical Oncologist PUC ???? - Survivorship - Cancer Genetic Counseling - Researcher | Individual | HCP |